Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

127.78USD
1:30am IST
Change (% chg)

$0.87 (+0.69%)
Prev Close
$126.91
Open
$127.67
Day's High
$128.71
Day's Low
$125.71
Volume
929,867
Avg. Vol
691,014
52-wk High
$157.02
52-wk Low
$109.12

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $27,182.25
Shares Outstanding(Mil.): 225.15
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): 68.60 29.41 30.38
EPS (TTM): 1.76 -- --
ROI: 3.22 13.85 13.36
ROE: 4.71 14.79 14.50

BRIEF-Alexion Pharmaceuticals Q1 non-GAAP earnings per share $1.38

* Raises FY 2017 non-GAAP earnings per share view $5.10 to $5.30

27 Apr 2017

UPDATE 2-Alexion Pharma names former Baxalta chief Ludwig Hantson CEO

March 27 Alexion Pharmaceuticals Inc on Monday named former Baxalta CEO Ludwig Hantson to its top job, as the rare-disease drug maker seeks to regain investor confidence following the exit of top management.

27 Mar 2017

Alexion Pharma names former Baxalta head Ludwig Hantson CEO

March 27 Alexion Pharmaceuticals Inc said it named former Baxalta head Ludwig Hantson chief executive officer as the rare-disease drug maker looks to steady the ship following the exit of its top management.

27 Mar 2017

BRIEF-Alexion appoints Ludwig Hantson as chief executive officer

* Alexion appoints Ludwig Hantson, Ph.D., as chief executive officer

27 Mar 2017

BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis

* Alexion submits application in Japan for soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage:

23 Mar 2017

BRIEF-Arbutus licenses LNP delivery technology to Alexion

* Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate

17 Mar 2017

Alexion to cut 7 pct of workforce

March 13 Alexion Pharmaceuticals Inc said on Monday it has initiated a company-wide restructuring that will affect about 7 percent of its workforce.

14 Mar 2017

BRIEF-Alexion Pharma says initiated companywide restructuring

* Alexion Pharmaceuticals says initiated companywide restructuring

14 Mar 2017

UPDATE 3-Alexion Pharma's revenue forecast allays investor fears

* 2017 rev forecast just under estimates, but reassuring-analysts

17 Feb 2017

BRIEF-Alexion interim CEO says looking for opportunities in M&A front

* Alexion CFO says "we're preparing for potential tax reform": conf call

16 Feb 2017

More From Around the Web

Competitors

Earnings vs. Estimates